<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3417">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524052</url>
  </required_header>
  <id_info>
    <org_study_id>DWJ1516101_India</org_study_id>
    <nct_id>NCT04524052</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19</brief_title>
  <official_title>Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of
      Niclosamide (DWRX2003) following escalating doses of DWRX2003 administered as an
      intramuscular injection in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>follow-up 48 days after dosing</time_frame>
    <description>AE rate, incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic changes of niclosamide from baseline in each dose group: Cmax</measure>
    <time_frame>follow-up 48 days after dosing</time_frame>
    <description>Maximum measured plasma concentration over the time span specified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic changes of niclosamide from baseline in each dose group: Tmax</measure>
    <time_frame>follow-up 48 days after dosing</time_frame>
    <description>Time of the maximum measured plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: CRP</measure>
    <time_frame>on Day 3, 7, 10 and 14</time_frame>
    <description>Change in C reactive protein levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>cohort 1 (144 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arms (both) 0.1 mL/site*2 sites Hips (both) 0.2 mL/site*2 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2 (432 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arms (both) 0.3 mL/site *2 sites Hips (both) 0.6 mL/site*2 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3 (960 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arms (both) 0.8 mL/site*2 sites Hips (both) 1.2 mL/site*2 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4 (1200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arms (both) 1.0 mL/site *2 sites Hips (both) 1.5 mL/site*2 sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWRX2003</intervention_name>
    <description>Intramuscularly injection at pre-defined injection sites</description>
    <arm_group_label>cohort 1 (144 mg)</arm_group_label>
    <arm_group_label>cohort 2 (432 mg)</arm_group_label>
    <arm_group_label>cohort 3 (960 mg)</arm_group_label>
    <arm_group_label>cohort 4 (1200 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscularly injection at pre-defined injection sites</description>
    <arm_group_label>cohort 1 (144 mg)</arm_group_label>
    <arm_group_label>cohort 2 (432 mg)</arm_group_label>
    <arm_group_label>cohort 3 (960 mg)</arm_group_label>
    <arm_group_label>cohort 4 (1200 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal healthy human adult male and female volunteers between 18-45 years (both ages
             inclusive) of age.

          2. Volunteers who agree to give written informed consent and are willing to participate
             in the study.

          3. Volunteer having bodyweight minimum of 50 kg.

          4. Volunteer having Body Mass Index of 18.50 to 29.90 Kg/m2 (both inclusive).

        Exclusion Criteria:

          1. Known allergic to Niclosamide or any component of the formulation and to any other
             related drug.

          2. History or presence of significant cardiovascular, respiratory, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological or
             psychiatric disease.

          3. Female volunteers who are nursing mothers/lactating women or are found positive in
             beta hCG test.

          4. History/ current use of Alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

